-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Recruiting
More
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma
cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of
ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change
in disease activity will be assessed.
ABBV-453 is an investigational drug being developed for the treatment of R/R MM. This study
will include a dose escalation phase to determine the best dose of ABBV-453. Approximately 21
adult participants with R/R MM will be enrolled in the study in approximately 12 sites
worldwide.
Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at an approved
institution (hospital or clinic). The effect of the treatment will be frequently checked by
medical assessments, blood tests, and side effects.
Stanford Investigators
View full details
-
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Recruiting
More
This study will test the hypothesis that in patients with previous daratumumab exposure,
combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher
complete remission (CR) rates in relapsed/refractory amyloidosis than historical
pomalidomide/dexamethasone treatment.
Stanford Investigators
View full details
-
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Not Recruiting
More
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric
Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple
myeloma.
The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The
dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of
increasing dose levels of CC-98633 to establish a recommended Phase 2 dose RP2D(s); and the
dose-expansion part (Part B) of the study is to further evaluate the safety,
pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D(s).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
Recruiting
More
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and
create free light chains that cannot be broken down. These free light chains bind together to
form amyloid fibrils that build up in the extracellular space of organs, affecting the
kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody
that removes AL amyloid deposits from tissues and organs, improves overall survival and it is
safe and well tolerated in patients with stage IIIa AL amyloidosis.
Stanford Investigators
View full details
-
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Recruiting
More
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and
create free light chains that cannot be broken down. These free light chains bind together to
form amyloid fibrils that build up in the extracellular space of organs, affecting the
kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody
that removes AL amyloid deposits from tissues and organs, improves overall survival and it is
safe and well tolerated in patients with stage IIIb AL amyloidosis.
Stanford Investigators
View full details
-
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Not Recruiting
More
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free
light chains that cannot be broken down. These free light chains bind together to form
amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys,
heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine the recommended dose of CAEL-101 to
facilitate progression of further clinical trials and evaluate safety and tolerability of
CAEL-101 in combination with the standard of care (SoC)
cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab .
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Recruiting
More
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and
immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory
multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine
and/or cyclophosphamide, or ALLO-647 alone.
Stanford Investigators
View full details
-
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Not Recruiting
More
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple
myeloma (MM) and what side effects (unwanted effects) may occur.
The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself.
This part of the study will find out how much SEA-BCMA should be given for treatment and how
often. It will also find out how safe the treatment is and how well it works.
In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Part D,
participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and
pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the
study will find out whether these drugs are safe when used together.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Not Recruiting
More
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Not Recruiting
More
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus
cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in
treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase II clinical trial studies how well dasatinib followed by stem cell transplant
works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may
interfere with the ability of cancer cells to grow and spread. Giving more than one drug
(combination chemotherapy) and giving dasatinib together with chemotherapy may kill more
cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joselene Sipin-Sayno, 6507368113.
Stanford Investigators
View full details
-
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Recruiting
More
This is a Phase Ib, open-label, multicenter, global study designed to assess the safety and
tolerability of RO6870810 as monotherapy and in combination with daratumumab in participants
with relapsed/refractory multiple myeloma. Each treatment cycle will be 21 days in length.
There are two parts to this study. A dose-escalation phase (Part I) will be used to evaluate
the safety and tolerability and dose limiting toxicities, and to establish the maximum
tolerated dose (MTR)/optimum biological dose (OBD) of RO6870810 when given as monotherapy or
in combination with daratumumab. A dose-expansion phase (Part II) will further characterize
the safety, tolerability and activity of RO6870810 as monotherapy or in combination with
daratumumab at the defined expansion dose-levels.
Stanford Investigators
View full details
-
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Not Recruiting
More
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring
additional treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kashif Naseem, 650-724-3155.
Stanford Investigators
View full details
-
Study of bb2121 in Multiple Myeloma
Not Recruiting
More
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in
adults with relapsed/refractory multiple myeloma (MM).
Stanford is currently not accepting patients for this trial.
For more information, please contact Reneth Tien, 650-723-0646.
Stanford Investigators
View full details
-
Longterm Follow-up of Subjects Treated With bb2121
Not Recruiting
More
This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up
study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study,
that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B
cell maturation antigen (BCMA)-expressing multiple myeloma.
bb2121 is defined as autologous T lymphocytes (T cells) transduced ex vivo with anti-BCMA02
CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA
suspended in cryopreservative solution. bb2121 is administered in subjects 1 time (or
retreated if retreatment criteria are met) in parent clinical study. No investigational
treatment will be administered in this study.
After completing the parent study, eligible subjects will be followed for up to 15 years
after their last bb2121 infusion in the parent study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Not Recruiting
More
This study evaluates the value of bortezomib in combination with specified chemotherapies for
the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Uzma Ahmed, 650-723-0670.
Lead Sponsor
Stanford Investigators
View full details
-
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Not Recruiting
More
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at
increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or
refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2
dose (RP2D) and schedule. The Phase 2 portion of the study will evaluate the efficacy of
inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in
second or later salvage status.
Stanford is currently not accepting patients for this trial.
For more information, please contact Vani Jain, 6507255459.
Stanford Investigators
View full details
-
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Not Recruiting
More
The primary objective of this study is to evaluate the safety of entospletinib in combination
with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or
refractory B-cell lineage acute lymphoblastic leukemia (ALL).
This is a dose escalation study in which after 2 induction cycles participants may be put on
maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase II trial is studying the side effects of giving combination chemotherapy together
with or without donor stem cell transplant and to see how well it works in treating patients
with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving
chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the
growth of cancer cells. It also stops the patient's immune system from rejecting the donor's
stem cells. The donated stem cells may replace the patient's immune cells and help destroy
any remaining cancer cells (graft-versus-tumor effect).
Stanford is currently not accepting patients for this trial.
For more information, please contact Vani Jain, 6507255459.
Stanford Investigators
View full details
-
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Not Recruiting
More
The rationale for this study is to provide additional treatment with NEOD001 for subjects who
complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability.
All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be
continued in this study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Not Recruiting
More
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled,
two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered
intravenously in adults with AL amyloidosis who had a hematologic response to previous
treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT])
and have persistent cardiac dysfunction.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Not Recruiting
More
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm
efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will
remain on-study until study completion, which will occur when all primary endpoint events
(all-cause mortality or cardiac hospitalizations) have been reached.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Not Recruiting
More
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose
of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Not Recruiting
More
This phase I trial studies the side effects and best dose of inotuzumab ozogamicin when given
together with combination chemotherapy in treating patients with relapsed or refractory acute
leukemia. Immunotoxins, such as inotuzumab ozogamicin, can find cancer cells that express
cluster of differentiation (CD)22 and kill them without harming normal cells. Drugs used in
chemotherapy, such as cyclophosphamide, vincristine sulfate, and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving inotuzumab ozogamicin together with combination chemotherapy may
kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kevin Morrison, 650-725-5450.
Stanford Investigators
View full details
-
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Not Recruiting
More
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have
not been approved in the combination for multiple myeloma or any other type of cancer.
Bortezomib is currently approved by the FDA for the treatment of multiple myeloma.
Lenalidomide is approved for use with dexamethasone for patients with multiple myeloma who
have received at least one prior therapy and for the treatment of certain types of
myelodysplastic syndrome (another type of cancer affecting the blood). Dexamethasone is
commonly used, either alone, or in combination with other drugs, to treat multiple myeloma.
Please note that Bortezomib and Lenalidomide are provided to patients participating in this
trial at no charge. Melphalan and cyclophosphamide, the drugs used during stem cell
collection and transplant, are also approved by the FDA. Melphalan is an FDA-approved
chemotherapy for multiple myeloma and is used as a high-dose conditioning treatment prior to
stem cell transplantation. Cyclophosphamide is used, either alone, or in combination with
other drugs, to treat multiple myeloma. These drugs have been used in other multiple myeloma
studies and information from those studies suggests that this combination of therapy may help
to treat newly diagnosed multiple myeloma.
In this research study, we are looking to explore the drug combination, lenalidomide,
bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation
to see what side effects it may have and how well it works for treatment of newly diagnosed
multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of
novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple
myeloma in younger patients. In this study, HDT as compared to conventional dose treatment
would be considered superior if it significantly prolongs progression-free survival by at
least 9 months or more, recognizing that particular subgroups may benefit more compared to
others.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Not Recruiting
More
This study will compare the efficacy, in terms of complete responses and overall survival, of
inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Not Recruiting
More
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30
subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and
pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Stanford Investigators
View full details
-
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Not Recruiting
More
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response
rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO)
ixazomib administered twice-weekly in combination with lenalidomide and low-dose
dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).
Stanford is currently not accepting patients for this trial.
For more information, please contact Vani Jain, 6507255459.
Stanford Investigators
View full details
-
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Not Recruiting
More
The primary objective for part 1 of the study is to determine the maximum tolerated dose
(MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary
objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated
at the MTD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leonel Gallegos, 6507232781.
Stanford Investigators
View full details
-
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Not Recruiting
More
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib
(VELCADE) in combination with pralatrexate in patients with previously treated multiple
myeloma, AL amyloid and Waldenstroem's macroglobulinemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ying Hao, 650-723-0646.
Lead Sponsor
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
young patients with newly diagnosed acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joselene Sipin-Sayno, 6507368113.
Stanford Investigators
View full details
-
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving epratuzumab together
with cytarabine and clofarabine may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab
together with cytarabine and clofarabine works in treating patients with relapsed or
refractory acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nini Estevez, 6507254041.
Stanford Investigators
View full details
-
Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
More
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety
and tolerability of magrolimab in combination with other anticancer therapies and to
determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with
relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab +
daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib +
dexamethasone.
The primary objective of this study for the Dose Expansion Cohorts is to evaluate the
efficacy of magrolimab in combination with other anticancer therapies in participants with
relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how
well it works compared to induction chemotherapy alone in treating patients with newly
diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase
(ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. It is not yet known whether
combination chemotherapy is more effective with or without blinatumomab in treating newly
diagnosed acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joselene Sipin-Sayno, 650-736-8113.
Stanford Investigators
View full details
